- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.09. | Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute | ||
| 01.09. | Mid-cap biotechs join Trump's latest round of drug pricing deals | ||
| 01.09. | Novartis says MS pill succeeds in two large studies | ||
| 01.09. | Alumis' TYK2 drug fails in key lupus study | ||
| 01.09. | Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns | ||
| 31.08. | FDA OKs Takeda, Protagonist drug for rare blood cancer | ||
| 31.08. | Lilly adds to immune drug pipeline with $2.9B Merida buyout | ||
| 31.08. | ESC '26: Cytokinetics' sell-off, Arrowhead's edge and a heart drug autopsy | ||
| 31.08. | The next frontier: Advancing foundation models with multimodal data | ||
| 28.08. | Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines | ||
| 28.08. | AstraZeneca, Ionis data spark debate about RNA drugs' impact on deadly heart disease | ||
| 28.08. | This week in charts: Biotech's rebound is undeniable | ||
| 28.08. | FDA green lights Priovant drug for rare skin disease | ||
| 27.08. | Michael Polansky has a new, skin-focused biotech. Don't call it a drug company. | ||
| 27.08. | New data could widen use of AstraZeneca, Amgen immune disease drug | ||
| 27.08. | Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say | ||
| 26.08. | Revolution drug heralded as a pancreatic cancer breakthrough cleared by FDA | ||
| 26.08. | Spyre tumbles as immune drug misses mark in rheumatoid arthritis | ||
| 26.08. | Biohaven trades cash for 'upside' with $795M epilepsy drug deal | ||
| 26.08. | Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial | ||
| 25.08. | New Jazz cancer drug approval could drive blockbuster sales | ||
| 25.08. | Roche, Eli Lilly get FDA nod for new Alzheimer's blood test | ||
| 25.08. | Will a 'reset' reignite investment in women's health startups? | ||
| 25.08. | Young startups miss out on biotech venture funding rebound, MassBio says | ||
| 24.08. | Safety concerns spur FDA to again halt testing of Regenxbio gene therapy |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.